Interferon Consensus Sequence-binding Protein Is Constitutively Expressed and Differentially Regulated in the Ocular Lens*

Wenmei LiDagger , Chandrasekharam N. NagineniDagger , Hong Ge§, Bassey Efiok, Ana B. Chepelinsky§, and Charles E. EgwuaguDagger parallel

From the Laboratories of Dagger  Immunology and § Molecular & Developmental Biology, NEI and the  Laboratory of Molecular Hematology, NHLBI, National Institutes of Health, Bethesda, Maryland 20892

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Interferon signaling is mediated by STATs and interferon regulatory factor (IRF) families of transcription factors. Ten distinct IRFs have been described and most are expressed in a variety of cells except for interferon consensus sequence-binding protein (ICSBP) and lymphoid-specific IRF/Pip that are thought to be exclusively expressed in lymphoid cells. We show here for the first time that ICSBP is constitutively and inducibly expressed in the mouse lens. In contrast to lymphoid cells with exclusive expression of ICSBP in the nucleus, ICSBP is present in both the cytoplasm and nucleus of the lens cell. However, ICSBP in the nucleus is of lower apparent molecular weight. We further show that the ICSBP promoter is constitutively bound by lens nuclear factors and that its activation requires binding of additional factors including STAT1. Furthermore, transcriptional activation of ICSBP gene by interferon gamma  is accompanied by selective nuclear localization of ICSBP in proliferating epithelial cells but not in the nuclei of nondividing cells in the lens fiber compartment. Constitutive and inducible expression of ICSBP in the ocular lens and differential regulation of its subcellular localization in the developing lens suggest that ICSBP may have nonimmunity related functions and that the commonly held view that it is lymphoid-specific be modified.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Interferons (IFNs)1 are a family of secreted proteins that are involved in the regulation of diverse cellular processes (1). In addition to their well defined roles in host defense against infectious agents, they have been associated with the regulation of cellular immunity, cell growth (1-3), and epithelial cell differentiation (4). The importance of IFNs is underscored by the expression of their receptors in virtually all mammalian cell types and by the fact that they regulate the expression of more than 50 cellular genes (1, 5). Interaction of IFNs with their cell surface receptor leads to activation of protein tyrosine kinases, JAK1, JAK2, or Tyk2, which in turn phosphorylate and activate members of a family of latent cytoplasmic transcription factors called STATs (signal transducers and activators of transcription) (6, 7). Phosphorylated STATs form homo- or heterodimers that translocate to the nucleus where they bind to well defined DNA sequences called GAS (gamma interferon activation site) or ISREs (IFN-stimulated response elements) and activate the transcription of genes coding for members of the interferon regulatory factor (IRF) family of transcription factors (8, 9).

IRFs are important mediators of transcriptional activation or repression of IFN-regulatable genes. They are characterized by a 115-amino acid N-terminal DNA-binding domain that interacts with ISRE motifs of IFN-regulatable genes (9). Direct and indirect evidence indicate that the C-terminal portion of IRFs contains a protein-protein interaction domain able to function as transcriptional activators and/or repressors (9, 10). Ten members of the IRF family have been identified, and they include ICSBP, ISGF3gamma /p48, IRF-1, IRF-2, IRF-3, IRF-4/lymphoid-specific IRF/Pip/ICSAT, IRF-5, IRF-6, IRF-7, and vIRF (9). IRF-1 and IRF-2 are the best characterized members of this family and were initially identified by studies of the transcriptional regulation of the human IFNbeta gene (11, 12). They have subsequently been shown to be key factors in the regulation of cell growth through their effects on the cell cycle (2, 3). IRF-1 is a tumor suppressor (13), whereas IRF-2 is oncogenic (14).

In contrast to IRF-1 and IRF-2, which are expressed in a variety of cell types, two IRF members, interferon consensus sequence-binding protein (ICSBP) (15) and lymphoid-specific IRF/Pip (Pu.1 interaction partner) (16-18) are thought to be expressed exclusively in cells of macrophage and lymphocyte lineages. Constitutive expression of ICSBP is thought to be limited to B lymphocytes, and mice with null mutation for the ICSBP gene develop myelogenous leukemia-like syndrome, suggesting that ICSBP activities may be restricted to lymphoid cells (15, 19).

We have previously reported the generation of transgenic mice with targeted ectopic expression of IFNgamma in the lens under the direction of the alpha A-crystallin promoter (20, 21). In these mice, the normal pattern of endogenous lens gene expression is perturbed, and the developmental fate of cells destined to become lens fiber cells is altered. It was during the course of studies to establish a biological link between expression of IFNgamma and the observed developmental defects that we discovered that several IRFs are constitutively expressed in the mouse lens. In this report, we present evidence that ICSBP is constitutively and inducibly expressed in the mouse lens.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Animals-- BALB/c wild type (WT) mice were purchased from Jackson Laboratories (Bar Harbor, ME). CD-1 WT mice were from Charles River (Raleigh, NC). Generation of the BALB/c IFNgamma transgenic (TR) mice has previously been described (20, 21). All animal procedures conformed to Institutional Guidelines and the Association for Research in Vision and Ophthalmology Resolution on the Use of Animals in Research.

Cell Culture and IFNgamma Treatment-- The murine lens epithelial cell line, alpha TN4-1 (22), kindly provided by Dr. Paul Russell (NEI, NIH, Bethesda, MD), was grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin. The CRLE2 and 1AMLE 6 mouse epithelial cell lines (23), kind gifts from Dr. Christina M. Sax (NEI, NIH), were propagated in minimum essential medium supplemented with 5% rabbit serum, 5% fetal bovine serum, 2 mM glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin. The cells were treated with murine recombinant IFNgamma (Life Technologies, Inc.) at a concentration of 100 units/ml for 2 h at 37 °C, 5% CO2. Some cells were propagated in medium containing the protein synthesis inhibitor, cycloheximide (CHX) (Sigma) at 35 µg/ml for 30 min followed by addition of IFNgamma and incubation for 2 h.

Reverse Transcribed PCR-- Lenses from 6-week-old WT or TR mouse littermates were carefully dissected and washed before RNA isolation to avoid any possible contamination by other tissues. Total RNA was isolated from the lenses or cultured lens cells as recommended for the TRIzol Reagent (Life Technologies, Inc.). All RNA samples were digested with RNase-free DNase 1 (Life Technologies, Inc.) for 30 min and purified by phenol/chloroform extraction and precipitation in 0.4 M LiCl. cDNA synthesis was performed at 42 °C for 1 h with 10 µg of total RNA, 0.3 µg of oligo(dT)(12-16) and 1000 units Superscript Reverse Transcriptase II (Life Technologies, Inc.) in a final volume of 50 µl. For each RNA preparation, a negative control reaction was performed without reverse transcriptase. After purification of the cDNA, hot start PCR assays were performed with AmpliTaq Gold DNA polymerase (Perkin-Elmer). Samples were incubated at 95 °C for 10 min to activate the AmpliTaq Gold, and amplification was carried out for 25 cycles at 94 °C for 45 s, 63 °C for 45 s, and 72 °C for 45 s, and this was followed by a final 10-min extension at 72 °C. All the primer pairs used for PCR amplifications spanned at least one intron, making it possible to distinguish between amplification products derived from cDNA and those resulting from any contaminating genomic DNA templates. The sequence of the PCR primers used are: for mouse G3PDH, 5'-TGAAGGTCGGTGTGAACGGATTTGGC-3' and 5'-CATGTAGGCCATGAGGTCCACCAC-3' (24), and for mouse ICSBP, 5'-GCTGCGG CAGTGGCTGATCGAACAGATCG-3' and 5'-AGTGGCAGGCCTGCACTGGGCTGCTG-3' (25). For Southern blot analysis, the amplified fragments were electrophoresed in agarose gels, transferred onto Hybond N+ nylon membrane (Amersham Pharmacia Biotech), and probed with fluorescein-dUTP 3'-end-labeled oligonucleotide probe, internal to the corresponding PCR primers. Probe labeling and signal detection were performed with the ECL 3'-oligolabeling and detection system (Amersham Pharmacia Biotech).

Northern Blot Analysis-- Total RNA (30 µg) was fractionated on a 0.8% agarose-formaldehyde gel, transferred to Hybond N+ membrane (Amersham Pharmacia Biotech), and hybridized for 12 h at 65 °C in hybridization solution containing 5 × 106 cpm/ml of probe as described (26). ICSBP or beta -actin-specific cDNA fragments were labeled to high specific activity (>108 cpm/µg) with [alpha -32P]dCTP by random priming (oligolabeling kit; Amersham Pharmacia Biotech) and used as hybridization probes. After two high stringency washes in 0.1 × SSC, 0.1% SDS at 65 °C, signals were detected by autoradiography at -70 °C. with Kodak X-Omat AR film and Cronex intensifying screens.

Western Blot Analysis-- Lenses derived from 6-week-old WT or TR mouse littermates were disrupted in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 2 µM leupeptin, 2 µM pepstatin, 0.1 µM aprotinin, 1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride, 0.5 mM phenylmethylsulfonyl fluoride, and 1 µM E-64 on ice. Extracts were clarified by centrifugation, and protein levels were determined by Coomassie Blue dye binding method as recommended for Coomassie Plus Protein Assay Reagent (Pierce). For analysis of the lens epithelial cell lines, cells were cultured for 2 h in medium alone or medium containing 100 units/ml IFNgamma . The cells were lysed and fractionated to cytosolic and nuclear fractions as described previously (27). Nuclear and cytosolic fractions were also obtained from the EL4 lymphoma cell line (ATCC TIB-39) (American Type Culture Collection, Manassas, VA) and BALB/c mouse spleen cells. All samples were heated for 10 min at 95 °C in 1× sample buffer and electrophoresed in 10% SDS/polyacrylamide gel. The gel was electroblotted onto polyvinylidene fluoride membrane, blocked with 5% nonfat milk, and probed with either goat anti-mouse ICSBP polyclonal antibodies (1:2000) from Santa Cruz Biotech (Santa Cruz, CA) or a rabbit anti-mouse ICSBP polyclonal antibody (1:2000) from Zymed Laboratories Inc. (San Francisco, CA). Mouse alpha A-crystallin-specific antibody was kindly provided by Sam Zigler (NEI, NIH). Preimmune serum was also used in parallel as control. Signals were detected with horseradish peroxidase-conjugated secondary F(ab')2 antibodies using the ECL system (Amersham Pharmacia Biotech).

Immunohistochemistry-- Seventeen day mouse embryos were fixed in 4% paraformaldehyde and embedded in Ameraffin tissue embedding medium (Baxter). Tissue sections (5 µm) were deparaffinized in xylene, rehydrated through a graded alcohol series, and used for immunostaining by the avidin-biotin-peroxidase complex method (Vector Laboratories, Burlingame, CA.). After preincubation for 30 min with 2% blocking serum, sections were incubated for 2 h at room temperature with antibodies (2 µg/ml) specific to mouse ICSBP (Santa Cruz). Control sections received the appropriate normal serum. In addition, antibody specificity control experiments were carried out by incubating the primary antibody with a 10-fold excess of a blocking peptide specific for the immunogenic epitope (ICSBP amino acid 407-425) for 2 h. The neutralized antibody was then used for immunostaining reactions with control tissue sections. All sections were subsequently incubated with biotinylated secondary antibody for 30 min at room temperature, and signal was visualized with diaminobenzidine-H2O2 as recommended (Vector). In some experiments, sections were counterstained with hematoxylin.

Electrophoretic Mobility Shift Assay-- Lens nuclear extracts were prepared either from 1-3-day-old WT CD-1 mouse lenses or cultured lens epithelial cells as described previously (28). Buffer used for nuclear protein extraction contained the following protease inhibitors: 2 µM leupeptin, 2 µM pepstatin, 0.1 µM aprotinin, 1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride, 0.5 mM phenylmethylsulfonyl fluoride, and 1 µM E-64. Protein concentration was determined by the Coomassie Blue dye binding as recommended for Coomassie Plus Protein Assay Reagen kit (Pierce), and extracts were stored at -70 °C until use. Nuclear extracts (10 µg) in binding buffer (20 mM HEPES, pH 7.9, 50 mM KCl, 10% glycerol, 0.5 mM dithiothreitol, 0.1 mM EDTA) containing 0.14 µg/µl poly(dI-dC) were incubated on ice for 10 min. 32P-Labeled double-stranded DNA probe (50,000 cpm) was added and incubated for an additional 20 min on ice. Samples were electrophoresed in 4% polyacrylamide gel in 0.5 × Tris borate-EDTA buffer. For competition experiments, the nuclear extract was preincubated with unlabeled probe and poly(dI-dC) for 20 min on ice prior to the addition of labeled probe. The sequences used for the double-stranded probes or competitors are: ICSBP pIRE/GAS, 5'-AGTGATTTCTCGGAAAGAGAGCGCTTC-3' (-175 to -149), and ICSBP-IRE, 5'-GTAAAGAGA GAAAAGGACTC-3' (-217 to -198) (25). For supershift assays, STAT1, STAT2, STAT3, or STAT4 antibody (Upstate Biotechnology Inc., Lake Placid, NY) was added to the binding buffer containing the nuclear extract and preincubated on ice for 10 min. The 32P-labeled probe was then added, and the entire mixture was incubated for an additional 20 min on ice before electrophoresis.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Constitutive and Inducible Expression of ICSBP in the Mouse Lens-- We had previously generated TR mice with ectopic expression of IFNgamma in the lens to study the paracrine effects of IFNgamma in the eye (20, 21). In this study, we examined mRNA and protein levels of IFNgamma -inducible transcription factors in the lenses of WT and TR mouse littermates to determine whether there is any correlation between enhanced expression of members of the IRF family of transcription factors and the abnormal lens phenotype observed in our TR mice. We found that both IRF-1 and IRF-2 are constitutively expressed in the lens and the levels of IRF-1 is markedly enhanced in the TR mouse lens (data not shown). Most surprising, we found ICSBP to be constitutively and inducibly expressed in the mouse lens as indicated by reverse transcribed PCR and Western blot analyses (Fig. 1). These results have been confirmed by six independent experiments, and the authenticity of the ICSBP transcripts has been verified by cDNA sequencing; the nucleotide sequence of the ICSBP transcripts isolated from the lens is identical to published sequences reported for ICSBP derived from mouse hematopoietic cells (15). Detection of ICSBP transcripts in the WT lens was unexpected because constitutive transcription of the ICSBP gene is thought to be restricted to B-lymphocytes (15, 19, 27). Analysis of rat and bovine lenses reveal that the ICSBP protein and mRNA are also expressed in these species (data not shown). This is the first time that constitutive expression or transcriptional activation of the ICSBP gene has been demonstrated in mammalian cells that are not directly involved in immunological responses.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 1.   ICSBP is constitutively expressed in mouse lens. Six-week-old BALB/c WT or IFNgamma TR mouse lenses were used to prepare whole lens extracts or poly(A) RNAs. A, reverse transcribed PCR and Southern blot analyses for expression of ICSBP and G3PDH mRNAs as indicated under "Experimental Procedures." Sizes of the amplified DNA fragments are: ICSBP, 627 base pairs; G3PDH, 983 base pairs. B, whole lens extracts from WT (75 µg protein/lane) and IFNgamma TR mouse (30 µg protein/lane) littermates were immunoblotted with antibodies specific for mouse ICSBP or alpha A-crystallin.

Spatial Localization of ICSBP Is Differentially Regulated in the Lens by IFNgamma -- As the vertebrate lens is comprised of undifferentiated, proliferating lens epithelial cells and terminally differentiated fiber cells, we sought to determine the spatial localization of cells expressing ICSBP in the lens. Fig. 2 shows ICSBP localization in embryonic day 17 TR and WT mouse eye sections using polyclonal antibodies specific to mouse ICSBP. In these experiments, three serial sections were fixed onto the same glass slide; one section served as a negative control and was incubated with normal preimmune serum, another section received the primary antibody, and the third section received the primary antibody and 10-fold excess of a neutralizing peptide specific to an immunogenic epitope of mouse ICSBP. In all six independent experiments performed, the experimental sections showed identical antibody-staining patterns, whereas the negative control section consistently showed no immunological reactivity. The section containing 10-fold molar excess of the peptide consistently showed no significant immunoreactivity. In some experiments the amount of the peptide was varied, and the neutralizing effect of the blocking peptide was found to be dose-dependent. As shown in Fig. 2, ICSBP protein is present in both the cytoplasm and nuclei of lens cells. In the TR mouse lens, intense nuclear localization of ICSBP is observed in cells at the lens equator (Fig. 2, C and D) and anterior epithelia (Fig. 2F) but not in nuclei of the cells at the lens fiber compartment (white arrows in Fig. 2, D and F). In the WT lens, the amount of ICSBP in the nucleus is very low and not easily detectable. However, cytoplasmic ICSBP is easily detectable, and the level in the lens epithelia appears to be higher compared with that of the fiber compartment (arrowhead in Fig. 2E). We obtained similar results using eye sections of mice at days 16-20 of embryonic development (data not shown).


View larger version (133K):
[in this window]
[in a new window]
 
Fig. 2.   Immunohistochemical localization of ICSBP in the developing mouse lens. Embryonic day 17 eye sections from WT BALB/c mouse (E) and IFNgamma TR BALB/c mouse (A---D and F) were incubated with affinity purified anti-mouse ICSBP antibody. Control section (A) was incubated with the primary antibody and 10-fold molar excess of an ICSBP peptide corresponding to the immunogenic epitope (mouse ICSBP amino acids 407-425). The anterior of the lens is oriented to the top. ICSBP immunostaining of nuclei of cells in the lens epithelia (F) and cells at the lens equator (C and D) is indicated by black arrows; nuclei in the fiber mass do not show significant DAB staining (white arrows in D and F). The sections in D-F are counter-stained with hematoxylin and eosin. f, lens fiber; r, retina; arrowhead, anterior epithelia; A and B, original magnification, 200×; C-F, original magnification, 1000×.

Cultured Lens Epithelial Cells Constitutively and Inducibly Express ICSBP-- As indicated by our immunolocalization studies, a significant amount of ICSBP expression occurs in the WT lens epithelia, and there is selective accumulation of the ICSBP protein in the nuclei of epithelial cells of the TR mouse lens. To confirm these results we examined well characterized lens epithelial cell lines for ICSBP expression. Three lens cell lines, alpha TN4-1, CRLE2, and 1AMLE6 were therefore treated with mouse IFNgamma in either the presence or absence of CHX and analyzed for constitutive or inducible expression of ICSBP. RNA was isolated from the various treatment groups and used for Northern analyses. In each of the cell lines, two ICSBP mRNAs of 3.0 and 1.7 kilobases are detected (Fig. 3A), and their sizes are similar to those of mouse ICSBP transcripts in hematopoietic cells (15, 25). In cells treated with IFNgamma , a significant increase in ICSBP is observed, indicating activation of the gene by IFNgamma . Treatment with CHX prior to addition of IFNgamma had no effects on the level of ICSBP transcripts, suggesting that inducible transcription of lens ICSBP mRNAs does not require de novo protein synthesis. In addition, cells that were treated for 2 h with IFNgamma and untreated cells were fractionated into cytoplasmic and nuclear fractions and analyzed for the presence of the ICSBP protein by Western blotting. As indicated in Fig. 3B, the ICSBP protein is detected in both the cytoplasm and nucleus. However, the ICSBP present in the nucleus migrates faster on SDS/polyacrylamide gel electrophoresis and appears to be of a lower apparent molecular weight. Cells that were not treated with IFNgamma were found to contain more ICSBP in the cytoplasm than in the nucleus. After treatment with IFNgamma , both higher and lower molecular weight ICSBP species are detected in the cytoplasm. However, the lower molecular weight species present in the nucleus is significantly increased. As shown in Fig. 3B, the ICSBP species detected in the lens cell nucleus co-migrates on SDS/polyacrylamide gel electrophoresis with the ICSBP of mouse lymphoid cells. Consistent with previous reports (27), neither mouse spleen cells nor the lymphoma cell line EL4 contain ICSBP in the cytoplasm.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 3.   ICSBP is constitutively and inducibly expressed in cultured lens epithelial cells. A, alpha TN4-1, CRLE2, and 1AMLE6 lens epithelial cell lines were cultured with (lanes 2, 5, and 8) or without IFNgamma (lanes 1, 4, and 7) or with IFNgamma and CHX (lanes 3, 6, and 9). Northern blot analysis (30 µg RNA/lane) was performed and hybridization was with 32P-labeled ICSBP or beta -actin cDNA probe as described under "Experimental Procedures." Sizes of the respective transcripts are indicated by the arrows to the right. B, detection of ICSBP by Western blot analysis. Lens cells cultured in medium with (+) or without (-) IFNgamma , EL4 mouse lymphoma cells, and purified BALB/c mouse spleen cells were fractionated into cytosolic (Cyt) or nuclear (Nuc) fractions and analyzed for ICSBP expression as described under "Experimental Procedures." kb, kilobases.

Constitutive and IFNgamma -inducible Lens Nuclear Factors Bind to ICSBP-GAS-- Transcriptional activation of the ICSBP gene by IFNgamma is mediated by the binding of activated STAT1 homodimers in the nucleus to the conserved cis regulatory palindromic IFNgamma -responsive GAS element, pIRE/GAS, present in the ICSBP gene at positions -147 to -175 (25). We therefore tested by electrophoretic mobility shift assay whether endogenous lens nuclear factors are able to bind pIRE/GAS. Analysis performed using nuclear extracts derived from WT mouse lens is shown in Fig. 4A. Two prominent DNA-protein complexes are formed with the pIRE/GAS probe, and formation of the complexes is competed by the unlabeled probe (Fig. 4A, lane 3), indicating that the interaction is specific. A DNA element located in the ICSBP gene at positions -191 to -217 and 22 base pairs upstream from the mouse pIRE/GAS site (25) contains a minimum ISRE motif (GAAANN) resembling the IRE or Pu box. This sequence, referred to as ICSBP-IRE (25), was used as a competitor to further characterize the ICSBP/GAS binding activities in the lens. The ICSBP-IRE probe allowed us to detect lens factors that bind to other DNA elements in the ICSBP promoter besides its GAS site. As shown in Fig. 4A, the IRE probe competed for the complex labeled b but not with the a complex (lane 4), indicating that there are factors in the lens that constitutively interact with GAS, as well as, non-GAS elements of the ICSBP promoter.


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 4.   A, lens nuclear factors interact with ICSBP GAS element. Lens nuclear extracts where prepared from newborn CD-1 mouse lenses and electrophoretic mobility shift assay analysis was performed using the pIRE/GAS (lane 2) as described under "Experimental Procedures." For the competition assays 100-fold excess of the unlabeled probe pIRE/GAS (lane 3) or ICSBP-IRE (lane 4) was incubated with the nuclear extract and labeled pIRE/GAS probe. DNA-protein complexes (a and b) are indicated by arrows to the left. Lane 1, labeled probe incubated without nuclear extract. B, ICSBP-GAS-binding nuclear factors are induced by IFNgamma in lens cells. Nuclear extracts (10 µg of protein) from alpha TN4-1 lens cells treated with IFNgamma (lanes 3, 7, 10, and 13) or with IFNgamma and CHX (lanes 4, 8, 11, and 14) or without IFNgamma (lanes 2, 6, 9, and 12) were incubated with 32P-labeled ICSBP-GAS (lanes 5-14) or ICSBP-IRE (lanes 1-4) probe. Incubation of extracts with unlabeled competitor probe, ICSBP-GAS (lanes 12-14) or ICSBP-IRE (lanes 9-11). Lanes 1 and 5, labeled probe incubated without nuclear extract. IFNgamma -induced protein-DNA complex is indicated as c; complex formed either in the presence or absence of IFNgamma treatment is indicated as d.

To further characterize the interaction between the ICSBP/pIRE and ICSBP-IRE elements with lens nuclear factors, we analyzed nuclear extracts derived from the various lens cell lines before and after treatment with IFNgamma . Typical results obtained from these studies are shown in Fig. 4B. Either probe formed a common complex (d) that is competed away by a 100-fold excess of either probe. Similar to results obtained using lens nuclear extracts, formation of this complex is also observed in extracts from cells that were not treated with IFNgamma (lanes 2 and 6), confirming that lens nuclear factors constitutively bind to these elements. An additional retarded band (c) was detected with the pIRE/GAS probe after treatment of the cells with IFNgamma (Fig. 4B, compare lanes 6 and 7), suggesting that these DNA binding activities are IFNgamma -inducible factors. pIRE/GAS-binding factors are also detected in cells treated with IFNgamma and CHX, indicating that expression of the binding activities does not require de novo protein synthesis (Fig. 4B, lane 8). Competition experiments with 100-fold excess of unlabeled probes revealed that the complex formed with the ICSBP pIRE motif after induction by IFNgamma is specific (lanes 13 and 14); the ICSBP-IRE probe is neither able to form the c complex nor compete in the formation of the c complex (lanes 10 and 11).

In hematopoietic cells, activation of ICSBP by IFNgamma is mediated by STAT1 binding to the pIRE/GAS element. It was therefore of interest to determine whether the pIRE/GAS binding activity in the lens extracts is STAT1 and/or any of the other members of the STAT family. Anti-STAT1 antibody supershifted the pIRE/GAS-protein complex (c) (data not shown). Antibodies specific to STAT2, STAT3, or STAT4 did not affect the c complex, suggesting that activation of ICSBP gene transcription in the lens is also mediated by STAT1.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Members of the IRF family of transcription factors differ in the range of cell types they are normally expressed in, their physiological inducers, and the distinct biological processes they affect (9). The IRF proteins identified to date include transcriptional activators (IRF-1 and ISGF3gamma ), transcriptional repressors (IRF-2 and ICSBP), and other members (lymphoid-specific IRF, IRF-3, IRF-5, IRF-6, IRF-7, and vIRF) whose functions are less well understood (1, 9). With the recent demonstration of a virally encoded homologue of cellular IRFs (29), it is likely that more IRFs will be identified and that previously described members would be found to possess new functions. The results of this study provide the first demonstration that the IRF member, ICSBP, is constitutively and inducibly expressed in the embryonic and adult mouse lens. Expression of ICSBP in the lens is unequivocally demonstrated at the RNA and protein levels, and its authenticity has been confirmed by cDNA sequencing. The ICSBP protein and mRNA are also expressed in rat and bovine lenses, suggesting that other mammals constitutively express ICSBP in their lenses.

Constitutive expression of ICSBP is thought to be limited to B lymphocytes and is not observed in virgin or resting T cells, macrophages, bone marrow, or thymus (15, 27, 30). However, transcription of the ICSBP gene has been shown to be inducible by either IFNgamma or antigenic stimulation in T cells and macrophages but not nonhematopoietic cells (27, 30). As part of the immunologically privileged environment of the anterior chamber of the eye, the avascular adult lens has no interactions with the immune system and thus would not be expected to come in direct contact with immunological effector molecules. What then is the functional relevance in the lens of ICSBP, a transcription factor whose functions are thought to be restricted to the ontogenesis and regulation of immunological responses by macrophages and lymphocytes? It is of note that ICSBP expression has been reported in the chicken (31, 32). The avian protein is expressed not only in cells of the lymphoid system but also in fibroblasts, suggesting that the transcriptional regulatory activities of ICSBP may not be restricted to lymphocytes and hematopoietic cells.

The data presented here suggest that the expression of the ICSBP gene in the lens may be under regulation by endogenous lens nuclear factors that constitutively bind cis regulatory DNA elements present in the mouse ICSBP promoter. The data further reveal that transcriptional activation of the ICSBP gene in lens cells is mediated by the additional binding of IFNgamma -activable factors to the GAS element in the proximal ICSBP promoter. Supershift assays using antibodies specific to various members of the STAT family of transcription factors revealed that STAT1 is one of the IFNgamma -inducible binding activities. Although our results indicate that the ICSBP protein in the lens possesses essential characteristics previously described for ICSBP in hematopoietic cells, electrophoretic mobility shift assay analyses using ICSBP-pIRE/GAS or ICSBP-IRE probe reveal subtle differences in the nuclear factors that interact with the ICSBP gene in lymphoid and lens cells. Whereas in EL4 lymphoid cells specific binding to either the pIRE/GAS or IRE probe was observed only after treatment with IFNgamma (25), lens nuclear factors bind to either element constitutively, as well as, after IFNgamma treatment. Furthermore, the IFNgamma -inducible binding activity in lens cells appear to be distinct from those in lymphoid cells because the former is resistant to CHX and consisted of multiple supershifted bands (data not shown), whereas the latter is sensitive to CHX, consists of a single band, and requires de novo protein synthesis (25). Differential sensitivity to CHX of IFNgamma -inducible factors that interact with the ICSBP-GAS element suggests that distinct factors regulate ICSBP gene in different cell types.

In hematopoietic cells, expression of ICSBP is primarily localized in the nucleus (27). Here we show that ICSBP is present in both the cytoplasm and nucleus of lens epithelial cells. In fact, in the unstimulated lens cell, the level of the ICSBP protein in the cytoplasm is higher than in the nucleus. Our immunolocalization studies on embryonic WT mouse eye sections further show that the level of ICSBP expression is significantly higher in the epithelial compartment of the lens, which exclusively contains undifferentiated, proliferating cells. Similar to lens epithelial cells in culture, the ICSBP protein is predominantly localized in the cytoplasm. However, significant nuclear localization of the ICSBP protein is observed in response to IFNgamma signaling. This occurs exclusively in the proliferating lens cells but not in nondividing cells at the lens fiber compartment, suggesting that response to STAT1 signaling in the lens may be restricted to the lens epithelia. Interestingly, the ICSBP proteins in the cytoplasmic and nuclear compartments differ in size. The ICSBP protein in the cytoplasm is of a higher apparent molecular weight, suggesting that nuclear localization of ICSBP is accompanied by post-translational modification. We are currently examining whether the lower molecular weight ICSBP species detected in the lens cell nucleus derives from dephosphorylation of ICSBP or if it is the product of an alternatively spliced ICSBP transcript.

Previous studies have shown that ICSBP is constitutively phosphorylated and that phosphorylation events can modulate the ability of ICSBP to bind DNA; ICSBP can bind DNA either through its association with other IRFs or directly when it is not tyrosine-phosphorylated (33, 34). Cytoplasmic expression of ICSBP in the normal lens and differential regulation of its spatial and subcellular localization in response to extracellular stimuli suggest that ICSBP may have distinct functions at different subcellular and/or spatial locations. Thus, the nuclear ICSBP may function as a transcription factor in the proliferating epithelia, whereas the ICSBP in the cytoplasm may have regulatory roles through protein-protein interactions with other IRFs, such as IRF-1 and IRF-2, which are also present in the cytoplasm of lens cells.2 It is important to note that selective localization to either the cytoplasm or nucleus has also been observed for other lens proteins. For example, the cyclin-dependent kinase 5, a protein associated with the elongation and denucleation of differentiating fiber cells, is present in the cytoplasm of both epithelial and fiber cells of the rat lens. However, in the final stages of lens differentiation, immediately prior to denucleation, the cyclin-dependent kinase 5 protein localizes to the nuclei of fiber cells (35). Furthermore, cyclin B2 localizes to the cytoplasm of proliferating cells in the epithelia and to the nuclei of primary fibers of the chicken lens (36). Differential localization of proteins to distinct subcellular compartments may therefore be an important regulatory mechanism by which specific biochemical pathways are temporally and spatially segregated in the vertebrate lens.

Although several studies indicate that ICSBP is primarily a transcriptional repressor in lymphoid and hematopoietic cells, the exact mechanisms by which it mediates its regulatory activities on gene transcription is largely unknown. Much is still to be learned about its interaction with other IRFs and the cross-talk between members of the IRF family. The noninnervated and avascular vertebrate lens has traditionally been found to be a useful in vivo experimental system for studying the function of several proteins because of its anatomic position within the eye, an organ that is segregated from the rest of body, and the fact that it consists of only two cell types of a common embryonic origin. Our demonstration that ICSBP is constitutively expressed in the lens therefore provides a unique opportunity to study its nonimmunity-related functions without many confounding effects associated with analysis of more complex tissues that are also exposed to lymphoid and hematopoietic cells. Further studies are needed to identify IRF-regulated proteins in the lens and how they are regulated by ICSBP and the other IRFs present in this tissue. It is equally important to elucidate the functional relevance of nuclear and cytoplasmic ICSBP and the regulatory mechanisms that may control its sequestration in the cytoplasm and subsequent translocation to the nucleus in response to extracellular stimuli.

    ACKNOWLEDGEMENTS

We are grateful to Drs. Peggy Zelenka, Graeme Wistow, and Jen-Yue Tsai for critical reading of the manuscript; Drs. Paul Russell and Christina M. Sax for providing the lens epithelial cell lines; Dr. Samuel Zigler for providing the mouse alpha A-crystallin-specific antibody; Nicole Newman for preparation of the histological sections; Ricardo Dreyfus, Shauna Everett, Wayne Randolph, John Ward, Gary Best, and Hassan Ennaciri for photographic assistance; and Rashid Mahdi for assistance in DNA and reverse transcribed PCR analysis.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

parallel To whom correspondence should be addressed: Lab. of Immunology, National Eye Institute, 10/10N116, 10 Center Dr., 1858, NIH, Bethesda, MD 20892.

2 W. Li, C. N. Nagineni, H. Ge, B. Efiok, A. B. Chepelinsky, and C. E. Egwuagu, unpublished data.

    ABBREVIATIONS

The abbreviations used are: IFN, interferon; IRF, interferon regulatory factor; ICSBP, interferon consensus sequence-binding protein; WT, wild type; TR, transgenic; CHX, cycloheximide; PCR, polymerase chain reaction.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Boehm, U., Klamp, T., and Howard, J. C. (1997) Annu. Rev. Immunol. 15, 749-795[CrossRef][Medline] [Order article via Infotrieve]
  2. Taniguchi, T., Harada, H., and Lamphier, M. (1995) L. Cancer Res. Clin. Oncol. 121, 516-520
  3. Vaughan, P. S., van Wijnen, A. J., Stein, J. L., and Stein, G. S. (1997) J. Mol. Med. 75, 348-359[CrossRef][Medline] [Order article via Infotrieve]
  4. Saunders, N. A., and Jetten, A. M. (1994) J. Biol. Chem. 269, 2016-2022[Abstract/Free Full Text]
  5. Valente, G., Ozmen, L., Novelli, F., Geuna, M., Palestro, G., Forni, G., and Garotta, G. (1992) Eur. J. Immunol. 22, 2403-2412[Medline] [Order article via Infotrieve]
  6. Darnell, J. E., Jr. (1997) Science 277, 1630-1635[Abstract/Free Full Text]
  7. Schindler, C., and Darnell, J. E., Jr. (1995) Annu. Rev. Biochem. 64, 621-651[CrossRef][Medline] [Order article via Infotrieve]
  8. Decker, T., Kovarik, P., and Meinke, A. (1997) J. Interferon Cytokine Res. 17, 121-134[Medline] [Order article via Infotrieve]
  9. Nguyen, H., Hiscott, J., and Pitha, P. M. (1997) Cytokine Growth Factor Rev. 8, 293-312[CrossRef][Medline] [Order article via Infotrieve]
  10. Sharf, R., Azriel, A., Lejbkowicz, F., Winograd, S. S., Ehrlich, R., and Levi, B.-Z. (1995) J. Biol. Chem. 270, 13063-13069[Abstract/Free Full Text]
  11. Miyamoto, M., Fujita, T., Kimura, Y., Maruyama, M., Harada, H., Sudo, Y., Miyata, T., and Taniguchi, T. (1988) Cell 54, 903-913[Medline] [Order article via Infotrieve]
  12. Harada, H., Fujita, T., Miyamoto, M., Kimura, Y., Maruyama, M., Furia, A., Miyata, T., and Taniguchi, T. (1989) Cell 58, 729-739[Medline] [Order article via Infotrieve]
  13. Taniguchi, T. (1997) J. Cell. Physiol. 173, 128-130[CrossRef][Medline] [Order article via Infotrieve]
  14. Vaughan, P. S., Aziz, F., van Wijnen, A. J., Wu, S., Harada, H., Taniguchi, T., Soprano, K. J., Stein, J. L., and Stein, G. S. (1995) Nature 377, 362-365[CrossRef][Medline] [Order article via Infotrieve]
  15. Driggers, P. H., Ennist, D. L., Gleason, S. L., Mak, W.-H., Marks, M. S., Levi, B.-Z., Flanagan, J. R., Appella, E., and Ozato, K. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 3743-3747[Abstract]
  16. Eisenbeis, C. F., Singh, H., and Storb, U. (1995) Genes Dev. 9, 1377-1387[Abstract]
  17. Matsuyama, T., Grossman, A., Mittrucker, H.-W., Siderovski, D. P., Kiefer, F., Kawakami, T., Richardson, C. D., Taniguchi, T., Yoshinaga, S. K., and Mak, T. W. (1995) Nucleic Acids Res. 23, 2127-2136[Abstract]
  18. Yamagata, T., Nishida, J., Tanaka, T., Sakai, R., Mitani, K., Yoshida, M., Taniguchi, T., Yazaki, Y., and Hirai, H. (1996) Mol. Cell. Biol. 16, 1283-1294[Abstract]
  19. Holtschke, E., Lohler, J., Kanno, Y., Fehr, T., Giese, N., Rosenbauer, F., Lou, J., Knobeloch, K., Gabriele, L., Waring, J. F., Bachmann, M. F., Zinkernagel, R. M., Morse, H. C., III, Ozato, K., and Horak, I. (1996) Cell 87, 307-317[Medline] [Order article via Infotrieve]
  20. Egwuagu, C. E., Sztein, J., Chan, C. C., Reid, W., Mahdi, R., Nussenblatt, R. B., and Chepelinsky, A. B. (1994) Invest. Ophthalmol. Visual Sci. 35, 332-341[Abstract]
  21. Egwuagu, C. E., Sztein, J., Chan, C. C., Mahdi, R., Nussenblatt, R. B., and Chepelinsky, A. B. (1994) Dev. Biol. 166, 557-568[CrossRef][Medline] [Order article via Infotrieve]
  22. Yamada, T., Nakamura, T., Westphal, H., and Russell, P. (1990) Curr. Eye Res. 9, 31-37[Medline] [Order article via Infotrieve]
  23. Sax, C. M., Dziedzic, D. C., Piatigorsky, J., and Reddan, J. R. (1995) Exp. Eye Res. 61, 125-127[Medline] [Order article via Infotrieve]
  24. Sabath, D. E., Broome, H. E., and Prystowsky, M. B. (1990) Gene (Amst.) 91, 185-191[CrossRef][Medline] [Order article via Infotrieve]
  25. Kanno, Y., Kozak, C. A., Schindler, C., Driggers, P. H., Ennist, D. L., Gleason, S. L., Darnell, J. E., Jr., and Ozato, K. (1993) Mol. Cell. Biol. 3, 3951-3963
  26. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Stuhl, K. (1995) Current Protocols in Molecular Biology, pp. 4.9-4.10, John Wiley & Sons, Inc., New York
  27. Politis, A. D., Ozato, K., Coligan, J. E., and Vogel, S. N. (1994) J. Immunol. 152, 2270-2278[Abstract/Free Full Text]
  28. Schreiber, E., Matthias, P., Muller, M. M., and Schaffner, W. (1989) Nucleic Acids Res. 17, 6419[Medline] [Order article via Infotrieve]
  29. Moore, P. S., Boshoff, C., Weiss, R. A., and Chang, Y. (1996) Science 274, 1739-1744[Abstract/Free Full Text]
  30. Nelson, N., Kanno, Y., Hong, C., Cantursi, C., Fujita, T., Fowlkes, B. J., O'Connell, E., Hu-li, J., Paul, W. E., Jankovic, D., Sher, A. F., Coligan, J. E., Thorton, A., Appella, E., Yang, Y., and Ozato, K. (1996) J. Immunol. 156, 3711-3720[Abstract]
  31. Junwirth, C., Rebbert, M., Ozato, K., Degen, H. J., Schultz, U., and Dawid, I. B. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 3105-3109[Abstract]
  32. Dosch, E., Zoller, B., Redmann-Muller, I., Nanda, I., Schmid, M., Viciano-Gofferge, A., and Jungwirth, C. (1998) Gene (Amst.) 210, 265-275[CrossRef][Medline] [Order article via Infotrieve]
  33. Sharf, R., Meraro, D., Azriel, A., Thornton, A. M., Ozato, K., Petricoin, E. F., Larner, A. C., Schaper, F., Hauser, H., and Levi, B.-Z. (1997) J. Biol. Chem. 272, 9785-9792[Abstract/Free Full Text]
  34. Bovolenta, C., Driggers, P. H., Marks, M. S., Medin, J. A., Politis, A. D., Vogel, S. N., Levy, D. E., Sakaguchi, K., Appella, E., Coligan, J. E., and Ozato, K. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 5046-5050[Abstract]
  35. Gao, C. Y., Zakeri, Z., Zhu, Y., He, H., and Zelenka, P. S. (1997) Dev. Genet. 20, 267-275[CrossRef][Medline] [Order article via Infotrieve]
  36. Gao, C. Y., Bassnett, S., and Zelenka, P. S. (1995) Dev. Biol. 169, 185-194[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.